



(12) Translation of
european patent specification

(11) NO/EP 2853545 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/42 (2006.01)
A61K 39/395 (2006.01)
A61P 37/08 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.10.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.05.25
(86)	European Application Nr.	14188102.9
(86)	European Filing Date	2009.09.17
(87)	The European Application's Publication Date	2015.04.01
(30)	Priority	2008.09.17, US, 97819 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
(73)	Proprietor	Xencor Inc., 111 W. Lemon Avenue, Monrovia, CA 91016, US-USA
(72)	Inventor	Desjarlais, John R., 1030 North Michigan Avenue, Pasadena, CA 91104, US-USA Chu, Seung Y., 4613 Larwin Ave, Cypress, CA 90630, US-USA Horton, Holly M., 46 Parker Street, ActonMassachusetts 01720, US-USA
(74)	Agent or Attorney	Curo AS, Vestre Rosten 81, 7075 TILLER, Norge

(54)	Title	Antibody specific for IgE
(56)	References Cited:	US-A- 6 037 453 S. CHU ET AL.: "Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.", MOLECULAR IMMUNOLOGY, vol. 45, no. 15, 8 August 2008 (2008-08-08), pages 3926-3933, XP002498116, England S. WIGGINGTON ET AL.: "An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotypic inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb.", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 38, no. 2, 7 December 2007 (2007-12-07), pages 313-319, XP002555134, England

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav.

1. Antistoff omfattende:
 - a) en tung kjede med SEQ ID NO:42; og
 - b) en lett kjede med SEQ ID NO:40.
- 5 2. Nukleinsyreblanding omfattende:
 - a) en første nukleinsyre som koder for en tung kjede med SEQ ID NO:42; og
 - b) en andre nukleinsyre som koder for en lett kjede med SEQ ID NO:40.
3. Vertscelle som omfatter nukleinsyreblandingen ifølge krav 2.
4. Framgangsmåte for framstilling av et antistoff omfattende:
 - 10 a) kultivering av en vertscelle ifølge krav 3 under betingelser der antistoffet produseres; og
 - b) gjenvinning av antistoffet.